Show simple item record

dc.contributor.authorSaad, F.en
dc.contributor.authordel Rosario, P.en
dc.contributor.authorClarke, Noel Wen
dc.date.accessioned2024-07-31T09:57:15Z
dc.date.available2024-07-31T09:57:15Z
dc.date.issued2024en
dc.identifier.citationSaad F, del Rosario P, Clarke NW. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. EUROPEAN UROLOGY. 2024 JUN;85(6):e178-e9.en
dc.identifier.pmid38042647en
dc.identifier.doi10.1016/j.eururo.2023.11.015en
dc.identifier.urihttp://hdl.handle.net/10541/627107
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.eururo.2023.11.015en
dc.titleOlaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trialen
dc.typeOtheren
dc.contributor.departmentThe Christie NHS Foundation Trusts and University of Manchester, Manchester, UKen
dc.identifier.journalEuropean Urologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record